Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 11, 2008, Pages 3328-3332

  Tamiya, Junko ^a   Dyck, Brian ^a   Zhang, Mingzhu ^a   Phan, Kasey ^a   Fleck, Beth A ^a   Aparicio, Anna ^a   Jovic, Florence ^a   Tran, Joe A ^a   Vickers, Troy ^a   Grey, Jonathan ^a   Foster, Alan C ^b   Chen, Chen ^a  

^a Neurocrine Bioscience   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inhibitor; Lipophilicity; Metabolic stability; Milnacipran; Monoamine transporter; Norepinephrine; Permeability; Serotonin; Stereoisomer; Structure activity relationship

Indexed keywords

ATOMOXETINE; MILNACIPRAN; MILNACIPRAN DERIVATIVE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER;

ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ISOMER; LIPOPHILICITY;

ANTIDEPRESSIVE AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLOPROPANES; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; NOREPINEPHRINE; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44149127089     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.025     Document Type: Article

References (27)

1. Preskorn S.H. J. Psychiatr. Pract. 10 (2004) 119
2. Spencer C.M., and Wilde M.I. Drugs 56 (1998) 405
3. Calculated log P values were 1.2 for milnacipran and 3.3 for atomoxetine using ACD software.
4. Puozzo C., and Leonard B.E. Int. Clin. Psychopharmacol. 11 (1996) 15
5. Puozzo C., Panconi E., and Deprez D. Int. Clin. Psychopharmacol. 17 (2002) S25
6. Puozzo C., Lens S., Reh C., Michaelis K., Rosillon D., Deroubaix X., and Deprez D. Clin. Pharmacokinet. 44 (2005) 977
7. Puozzo C., Hermann P., and Chassard D. Int. Clin. Psychopharmacol. 21 (2006) 153
8. Briley M. CNS Drugs Rev. 4 (1998) 137
9. Mochizuki D., Tsujita R., Yamada S., Kawasaki K., Otsuka Y., Hashimoto S., Hattori T., Kitamura Y., and Miki N. Psychopharmacology 162 (2002) 323
10. Vaishnavi S.N., Nemeroff C.B., Plott S.J., Rao S.G., Kranzler J., and Owens M.J. Biol. Psychiatry 55 (2004) 320
11. For recent review articles, see. Rooks D.S. Curr. Opin. Rheumatol. 19 (2007) 111
12. Leo R.J., and Brooks V.L. Curr. Opin. Investig. Drugs 7 (2006) 637
13. Bonnaud B., Cousse H., Mouzin G., Briley M., Stenger A., Fauran F., and Couzinier J.P. J. Med. Chem. 30 (1987) 318
14. Chen C., Dyck B., Fleck B.A., Foster A.C., Grey J., Jovic F., Mesleh M., Phan K., Tamiya J., Vickers T., and Zhang M. Bioorg. Med. Chem. Lett. 18 (2008) 1346
15. Roggen H., Kehler J., Stensbol T.B., and Hansen T. Bioorg. Med. Chem. Lett. 17 (2007) 2834
16. Doyle M.P., Davies S.B., and Hu W. Org. Lett. 2 (2000) 1145
17. Doyle M.P., and Wu W. Adv. Synth. Catal. 343 (2001) 299
18. Shuto S., Ono S., Hase Y., Kamiyama N., Takada H., Yamasihita K., and Matsuda A. J. Org. Chem. 61 (1996) 915
19. 4, filtered, and concentrated in vacuo. The crude product was purified by chromatography on silica gel using 3:1 hexane/EtOAc to afford lactone 17h (500 mg, 38% yield). For a recently published procedure, see:. Xu F., Murry J.A., Simmons B., Corley E., Fitch K., Karady S., and Tschaen D. Org. Lett. 8 (2006) 3885
20. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. J. Pharmacol. Exp. Ther. 283 (1997) 1305 (for experimental detail, see WO 07098356)
21. 50 values for the synaptosomal uptake inhibition of this isomer are reported by Roggen: 7 nM (NET), 120 nM (SERT) and 10,000 nM (DAT), see Ref. 11.
22. For assay conditions, see:. Guo Z., Zhu Y.F., Gross T.D., Tucci F.C., Gao Y., Moorjani M., Connors Jr. P.J., Rowbottom M.W., Chen Y., Struthers R.S., Xie Q., Saunders J., Reinhart G., Chen T.K., Bonneville A.L., and Chen C. J. Med. Chem. 47 (2004) 1259
23. Chalon S.A., Desager J.P., Desante K.A., Frye R.F., Witcher J., Long A.J., Sauer J.M., Golnez J.L., Smith B.P., Thomasson H.R., and Horsmans Y. Clin. Pharmacol. Ther. 73 (2003) 178
24. Sauer J.M., Ponsler G.D., Mattiuz E.L., Long A.J., Witcher J.W., Thomasson H.R., and Desante K.A. Drug Metab. Dispos. 31 (2003) 98
25. Puozzo C., Pozet N., Deprez F., Baille P., Ung H.L., and Zech P. Eur. J. Drug Metab. Pharmacokinet. 23 (1998) 280
26. Shitara Y., Horie T., and Sugiyama Y. Eur. J. Pharm. Sci. 27 (2006) 425
27. Linnet K., and Ejsing T.B. Eur. Neuropsychopharmacol. 18 (2008) 157